Name: Chinese firm refuses to honour pact on sharing Covid-19 vaccine tech with Bangladesh
Brand: economictimes.com
SKU: economictimes-com-15
Availability: OnlineOnly

critic

Chinese firm refuses to honour pact on sharing Covid-19 vaccine tech with Bangladesh

preview

Search+›››› Chinese firm refuses to honour pact on sharing Covid-19 vaccine tech with BangladeshBy , Last Updated: Oct 03, 2020, 10:46 PM ISTSynopsisNew Delhi: The much-hyped mass trial of a Chinese vaccine in Bangladesh has become uncertain and may even be a non-starter after drugmaker Ltd asked the to co-finance the initiative.Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the Bangladesh government provided funds, although the company was supposed to bear the costs as per an agreement.The Beijing-based vaccine giant sent the letter to the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), which was to conduct the trial."They [Sinovac] informed us that they would be able to start the trial soon if we co-fund the initiative. We will make a decision after talking to the prime minister," Abdul Mannan, secretary of the health services division at the health ministry, told leading Bangladesh English daily The Daily Star.“We are not dependent on Sinovac. The government is looking for other avenues to get the vaccine right after it is developed," Mannan told The Daily Star.The Sinovac letter did not mention how much fund it would need and why it was seeking funds at the last moment, according to The Daily Star.Experts told the newspaper that Sinovac's demand was "not fair" and speculated that the company might have run the required number of trials in other countries."They probably fulfilled their enrollment criteria for the approval. Now they are placing the financial burden on us," said Prof Sayedur Rahman, member of the ethical review committee of (BMRC).There is a requirement for human trials on 10,000 to 30,000 people to get any vaccine approved globally, he said.Prof Nazrul Islam, a member of the National Technical Advisory Committee (NTAC) on Covid-19, said, "This makes everything unclear. We recommended the trials considering the technology transfer, because that would have gotten us the vaccines at a cheaper rate”Bangladesh’s pharma major (BPL) has agreed to invest with (SII) in the effort to bring out an approved vaccine for Covid-19.Experience Your Economic Times Newspaper, The Digital Way!&nbsp;»(Catch all the , Events and Updates on .)Download to get Daily Market Updates &amp; Live Business News.Subscribe to XContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories &amp; personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &amp; in-depth stock reportsSubscribe NowTo read full story, subscribe to ET Prime₹34 per weekBilled annually at₹2499Already a Member? Super Saver Sale - Flat 30% OffOn ET Prime MembershipAlready a Member? Rs 49 for 1st monthThen Rs. 1,749 per yearValid only with UPI, Credit &amp; Debit Cards Autopay---Subscribe Now(Credit card mandatory)You can cancel your subscription anytime---Subscribe Now(Pay Using Netbanking/UPI/Debit Card)Netbanking, Credit &amp; Debit CardSubscribe with Google₹399MonthlyPLANBilled Amount ₹399No Trial Period₹399₹208(Save 49%)YearlyPLANBilled Amount ₹2,499₹399₹150(Save 63%)2-YearPLANBilled Amount ₹3,599$13.99(Save 40.0%)$33.99Get ET Prime for just ₹2499 ₹1749/yrSpecial OfferGet Flat 20% OffON ET PRIME MEMBERSHIPStories you might be interested inSUBMIT

Search+›››› Chinese firm refuses to honour pact on sharing Covid-19 vaccine tech with BangladeshBy , Last Updated: Oct 03, 2020, 10:46 PM ISTSynopsisNew Delhi: The much-hyped mass trial of a Chinese vaccine in Bangladesh has become uncertain and may even be a non-starter after drugmaker Ltd asked the to co-finance the initiative.Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the Bangladesh government provided funds, although the company was supposed to bear the costs as per an agreement.The Beijing-based vaccine giant sent the letter to the...

public

Dipanjan Roy Chaudhury

economictimes.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Chinese firm refuses to honour pact on sharing Covid-19 vaccine tech with Bangladesh

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS